Search

Search Constraints

You searched for: Author/Creator Shulman, Melanie

Search Results

1. Baseline biomarker (tau PET) characteristics from TANGO: A phase 2 trial of gosuranemab (BIIB092) in early Alzheimer's disease. (1st February 2022)

2. Baseline biomarker (tau PET) characteristics from TANGO: A phase 2 trial of gosuranemab (BIIB092) in early Alzheimer's disease. (December 2021)

3. Baseline characteristics from TANGO: Phase 2 study to evaluate gosuranemab (BIIB092) in patients with early Alzheimer's disease: Human: Improving clinical trial methodology. (7th December 2020)

4. Exploratory evaluation of 18F‐MK‐6240 tau PET positivity in TANGO phase 2 clinical trial of gosuranemab (BIIB092) in Mild Cognitive Impairment and mild Alzheimer's disease. (20th December 2022)